Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | TYMP | P19971 | 1/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.58 |
| ▸ | TYMS | P04818 | 6/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8326880 | 1.00 | LMNA (0.64) | LMNASMN1; SMN2TYMPHSP90AA1TYMS | |
| SCHEMBL3341212 | 0.93 | TYMS (0.56) | LMNASMN1; SMN2TYMPHSP90AA1TYMS | |
| SCHEMBL7703578 | 0.93 | TYMS (0.56) | LMNASMN1; SMN2TYMPHSP90AA1TYMS | |
| SCHEMBL3341208 | 0.93 | TYMS (0.56) | LMNASMN1; SMN2TYMPHSP90AA1TYMS | |
| SCHEMBL7703575 | 0.93 | TYMS (0.56) | LMNASMN1; SMN2TYMPHSP90AA1TYMS | |
| SCHEMBL9227960 | 0.89 | LMNA (0.67) | LMNASMN1; SMN2TYMPTYMSALOX12 | |
| SCHEMBL9227962 | 0.89 | LMNA (0.67) | LMNASMN1; SMN2TYMPTYMSALOX12 | |
| SCHEMBL10692639 | 0.88 | TK1 (0.64) | TYMPTYMS | |
| SCHEMBL10446716 | 0.88 | POLB (0.58) | TYMP | |
| SCHEMBL6334503 | 0.88 | POLB (0.58) | TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043467-A1 | 5'-SUBSTITUTED NUCLEOSIDE MONOPHOSPHATES, PRODRUGS THEREOF, AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2024-02-08 | — | — | US | disclosed |
| EP-4204428-A1 | 5'-SUBSTITUTED NUCLEOSIDE MONOPHOSPHATES, PRODRUGS THEREOF, AND USES RELATED THERETO | Emory University (US) | 2023-07-05 | — | — | EP | disclosed |
| WO-2022047400-A1 | 5'-SUBSTITUTED NUCLEOSIDE MONOPHOSPHATES, PRODRUGS THEREOF, AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2022-03-03 | — | — | WO | disclosed |
| US-5869464-A | HAVING LOW TOXICITY, SUSTAINING LOW CONCENTRATION IN BLOOD FOR EXTENDED PERIOD | TAIHO PHARMACEUTICAL CO. LTD. (JP) | 1999-02-09 | — | — | US | disclosed |
| EP-0686641-B1 | 2'-DEOXY-5-FLUOROURIDINE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESS FOR PRODUCING THE SAME, AND ANTITUMOR DRUG | TAIHO PHARMACEUTICAL CO LTD (JP) | 1998-08-26 | — | — | EP | disclosed |
| EP-0323441-B1 | 5-Fluorouracil derivatives | OTSUKA PHARMA CO LTD (JP) | 1996-04-24 | — | — | EP | disclosed |
| EP-0686641-A1 | 2'-DEOXY-5-FLUOROURIDINE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESS FOR PRODUCING THE SAME, AND ANTITUMOR DRUG | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1995-12-13 | — | — | EP | disclosed |
| EP-0301873-B1 | 2'-deoxy-5-fluorouridine derivatives | TAIHO PHARMACEUTICAL CO LTD (JP) | 1994-06-08 | — | — | EP | disclosed |
| EP-0247381-B1 | 5-FLUROROURACIL DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-08-04 | — | — | EP | disclosed |
| EP-0331032-B1 | 2'-DEOXY-5-FLUOROURIDINE DERIVATIVES | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1993-04-28 | — | — | EP | disclosed |
| US-4983609-A | Anticancer agents | OTSUKA PHARMACEUTICAL (JP) | 1991-01-08 | — | — | US | disclosed |
| EP-0400610-A1 | 5-Fluorouracil derivatives | UBE INDUSTRIES, LTD. (JP) | 1990-12-05 | — | — | EP | disclosed |
| EP-0331032-A1 | 2'-Deoxy-5-fluorouridine derivatives | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1989-09-06 | — | — | EP | disclosed |
| US-4864021-A | ANTICARCINOGENIC AGENTS, ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-09-05 | — | — | US | disclosed |
| EP-0323441-A2 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-07-05 | — | — | EP | disclosed |
| EP-0303269-A2 | 2'-Deoxy-5-fluorouridine derivatives, process for preparing the same and the use thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-02-15 | — | — | EP | disclosed |
| EP-0301873-A2 | 2'-deoxy-5-fluorouridine derivatives | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1989-02-01 | — | — | EP | disclosed |
| EP-0247381-A2 | 5-flurorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-12-02 | — | — | EP | disclosed |
| EP-0180897-A2 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-14 | — | — | EP | disclosed |
| EP-0180188-A2 | A composition for increasing the anti-cancer activity of an anti-cancer compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043467-A1 | 5'-SUBSTITUTED NUCLEOSIDE MONOPHOSPHATES, PRODRUGS THEREOF, AND USES RELATED THERETO | PNP, ENTPD5, TYMP | LMNA 3158/4885SMN1; SMN2 4446/4885TYMP 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.